Home › Companies › JBIO

Jade Biosciences

JBIO Rare disease Lead: Phase 2 8 Biotech Distilled articles ↓

Immunology Renal Protein

Most recent annual filing: 2026-03-06

Pipeline (6 active programs)

JADE101

Protein Target: APRIL

IgA Nephropathy Phase 2 subcutaneous Paragon

JADE201

Protein Target: BAFF-R

Rheumatoid Arthritis Phase 1 subcutaneous Paragon Therapeutics
Undisclosed indication Preclinical Paragon
Undisclosed indication
Undisclosed indication Preclinical Paragon

JADE301

Undisclosed indication Preclinical Paragon

Biotech Distilled coverage (8)

2026-07-01 UPDATE: Jade Biosciences (JBIO) - The Wildcard Option Got Exercised
2026-06-04 UPDATE: Jade Biosciences (JBIO) - The Deal Priced at the Floor of My Range
2026-06-03 UPDATE: Jade Biosciences (JBIO) - The Dilution I Telegraphed, Just Not Through the Door I Expected
2026-06-02 UPDATE: Jade Biosciences (JBIO) - The Monkey Translated. The Stock Dropped 11.6% Anyway. 🔒 Paid
2026-05-29 UPDATE: Jade Biosciences (JBIO) - The Binary Has a Date: Monday, 8:00 a.m. ET 🔒 Paid
2026-05-27 UPDATE: Jade Biosciences (JBIO) - Two First-Patient-Dosed PRs Before the Monkey-to-Human Verdict 🔒 Paid
2026-05-08 UPDATE: Jade Biosciences (JBIO) - The $200M ATM Lands 6 Weeks Before the Monkey-to-Human Verdict 🔒 Paid
2026-05-06 Jade Biosciences (JBIO) - Scientific Deep Dive for JADE101 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.